Related Experiment Video

Updated: May 9, 2026

In Vitro Model of Coronary Angiogenesis
08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Vascular endothelial growth factor in heart failure

Ziad Taimeh1, John Loughran, Emma J Birks

  • 1Department of Internal Medicine, University of Louisville School of Medicine, 550 South Jackson Street, Louisville, KY 40202, USA.

Nature Reviews. Cardiology
|July 17, 2013
PubMed

Insights

Vascular endothelial growth factor (VEGF) plays a key role in new blood vessel formation. This review explores VEGF

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Molecular Biology

Background:

  • Heart failure involves a critical imbalance in oxygen supply and demand.
  • Dysfunctional blood vessel formation is a hallmark of advanced heart failure.
  • Vascular endothelial growth factor (VEGF) is central to angiogenesis.

Purpose of the Study:

  • To review the biological role of VEGF in heart failure.
  • To examine the therapeutic potential of targeting VEGF for heart failure treatment.
  • To explore VEGF as an adjunct to stem cell therapy in heart failure.

Main Methods:

  • Literature review of preclinical and clinical investigations on VEGF in heart failure.
  • Analysis of clinical trial data for VEGF-targeted therapies.
  • Examination of VEGF's role in angiogenesis and stem cell interactions.

Main Results:

  • VEGF is crucial for new blood vessel formation in heart failure.
  • Previous clinical trials targeting VEGF alone have not shown benefit.
  • VEGF may have potential as adjuvant therapy with stem cells.

Conclusions:

  • Targeting VEGF alone has not proven effective for heart failure.
  • VEGF's role in angiogenesis warrants further investigation for therapeutic strategies.
  • Combining VEGF therapy with stem cell transplantation is a promising avenue.

More Related Videos

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Decellularization and Recellularization Methodology for Human Saphenous Veins11:35

Decellularization and Recellularization Methodology for Human Saphenous Veins

Published on: July 27, 2018

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...